Akero Therapeutics, Inc. - COMMON STOCK (AKRO)

Historical Holders from Q2 2019 to Q3 2025

Symbol: AKRO on Nasdaq
Type / Class: Equity / COMMON STOCK
Shares outstanding: 79,376,583
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 91,445,652
Holdings value: $4,342,080,475
% of all portfolios: 0.006%
Number of holders: 258
Number of buys: 115
Number of sells: -127
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Akero Therapeutics, Inc. - COMMON STOCK (AKRO)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
GENERAL ATLANTIC, L.P.	8.4%		$278,656,049		6,796,489		General Atlantic, L.P.	31 Mar 2025
JANUS HENDERSON GROUP PLC	7.9%	-6.7%	$298,188,881	-$21,757,757	6,280,305	-6.8%	JANUS HENDERSON GROUP PLC	30 Sep 2025
RTW INVESTMENTS, LP	7.3%	-25%	$304,707,219	-$51,180,398	5,873,308	-14.4%	RTW Investments, LP	30 Jun 2025
Deep Track Capital, LP	5.5%		$208,910,680		4,400,000		Deep Track Capital, LP	30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP	5.3%	+25%	$201,878,360	+$39,974,124	4,251,861	+24.7%	Wellington Management Group LLP	30 Sep 2025
PRICE T ROWE ASSOCIATES INC /MD/	4.8%		$180,902,408		3,810,076		T. Rowe Price Associates, Inc.	30 Sep 2025

Institutional Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	91,445,652	$4,342,080,475	-$45,117,892	$15,845,112	$49,954,982	$47.48	258
2025 Q2	92,131,681	$4,916,497,064	+$352,115,121	$46,011,207	$91,709,832	$53.36	253
2025 Q1	86,154,634	$3,503,843,061	+$531,433,647	$31,798,192	$40,994,096	$40.48	238
2024 Q4	74,174,925	$2,063,406,098	-$8,506,883	$14,460,836	$8,856,478	$27.82	188
2024 Q3	73,002,070	$2,094,264,742	+$38,454,830	$17,678,778	$6,851,172	$28.69	167
2024 Q2	71,810,586	$1,684,723,283	-$32,810,693	$3,129,564	$4,124,268	$23.46	152
2024 Q1	73,087,900	$1,845,988,959	+$363,844,050	$14,160,756	$10,775,916	$25.26	171
2023 Q4	58,426,478	$1,364,286,476	-$103,406,827	$4,450,510	$34,338,510	$23.35	153
2023 Q3	56,757,185	$2,870,716,263	+$69,098,588	$114,704,452	$92,490,588	$50.58	178
2023 Q2	56,372,656	$2,631,606,875	+$394,199,729	$32,751,529	$28,008,217	$46.69	156
2023 Q1	48,070,649	$1,839,011,256	-$64,149,034	$12,951,148	$18,463,736	$38.26	155
2022 Q4	48,581,649	$2,661,931,733	+$138,143,044	$29,257,720	$43,243,160	$54.8	159
2022 Q3	46,589,695	$1,586,331,269	+$490,029,839	$29,653,685	$17,408,185	$34.05	142
2022 Q2	34,862,359	$329,587,739	-$12,722,696	$0	$107,000	$9.45	107
2022 Q1	35,141,546	$498,682,069	-$2,941,499	$326,000		$14.19	98
2021 Q4	35,317,227	$746,760,550	+$3,654,957	$1,079,000		$21.15	96
2021 Q3	27,981,387	$625,678,377	+$7,096,019	$1,887,000		$22.35	102
2021 Q2	27,584,397	$684,200,429	-$121,336,833	$3,381,000	$0	$24.81	94
2021 Q1	31,507,544	$913,643,371	+$20,106,775	$16,346,000	$2,043,000	$29.01	109
2020 Q4	30,844,129	$813,955,792	+$45,233,337	$1,434,000	$0	$25.8	94
2020 Q3	28,988,756	$892,491,434	+$220,301,852	$1,398,000	$289,000	$30.79	103
2020 Q2	21,827,155	$543,916,299	-$2,246,835	$471,000	$0	$24.92	75
2020 Q1	22,025,386	$466,923,796	+$63,234,074		$297,000	$21.2	66
2019 Q4	19,000,379	$421,605,474	+$18,157,481			$22.19	57
2019 Q3	12,742,598	$288,264,741	+$54,821,814			$22.75	54
2019 Q2	10,674,595	$204,526,000	+$204,526,000			$19.15	48